Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Trial number:
- NCT04816214
- Trial phase:
- 3
- Study type:
- Targeted therapy
- Overall status:
- Terminated
Study start date
Scientific title
Summary
Key
Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations known to be associated with EGFR TKI sensitivity, EGFR T790M negative and MET gene amplificationStage IIIB/IIIC or IV NSCLC Participants must have progressed on one prior line of therapy (1st/2nd generation EGFR TKIs, osimertinib or other third generation EGFR TKIs) for advanced/metastatic disease (stage IIIB/IIIC and must be candidates for platinum (cisplatin or carboplatin) - pemetrexed doublet based chemotherapy Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Participants must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1 Common Terminology Criteria Adverse Event 5.0 (CTCAE v 5.0) At least one measurable lesion as defined by RECIST 1.1 Participants must have adequate organ function
Key